The US Federal Trade Commission expanded its expectations so much in its updated advertising guidance health care products the agency should’ve considered proposing a rulemaking, a food and drug regulation attorney suggests.
“There are a couple of issues that I have with that guidance document,” said Claudia Lewis, a partner at Venable LLP in Washington and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?